Fig. 4From: Potential application of mesenchymal stromal cells as a new therapeutic approach in acute respiratory distress syndrome and pulmonary fibrosisTrends of C-reactive protein (CRP) levels of each patient at the time of enrollment (T0), within 24 h after the infusion of the first (T1) and second (T2) dose of BM-MSCs, administrated 15 days apartBack to article page